On October 12, 2018 Oncopeptides AB (Nasdaq Stockholm: ONCO) reported that they will present at Jefferies London Healthcare Conference on November 14th at 3.20 PM local time (GMT), the presentation will be webcasted (Press release, Oncopeptides, OCT 12, 2018, View Source [SID1234530258]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. Since the founding of the company, the focus has primarily been on the development of the lead product candidate melflufen (Ygalo), an alkylating peptide, belongs to a novel class of peptidase-enhanced compounds (PEnCs), intended for effective and focused treatment of hematological cancers, and in particular multiple myeloma.
Melflufen (Ygalo) has been used to treat late-stage RRMM patients in the phase II clinical study called O-12-M1 that is completed with favorable results which have been reported previously. Currently, Oncopeptides conduct four clinical trials with melflufen for the treatment of multiple myeloma. These are HORIZON, OCEAN, ANCHOR and BRIDGE.
The current clinical study program is intended to demonstrate better results from treatment with melflufen (Ygalo) compared to established alternative drugs for patients with late-stage multiple myeloma. This could potentially provide physicians with a new treatment option for patients suffering from this serious disease.
For further information, please contact:
Rein Piir, Head of Investor Relations at Oncopeptides AB
E-mail: [email protected]
This information was submitted for publication at 09.00 CET October 12, 2018